OTCMKTS:MRMD

MariMed (MRMD) Stock Forecast, Price & News

$0.41

-0.01 (-1.22%)

(As of 05:34 PM ET)

Compare

Today's Range: $0.40
▼
$0.44
50-Day Range: $0.37
▼
$0.52
52-Week Range: $0.28
▼
$0.77

Volume: 157,169 shs
Average Volume: 256,968 shs
Market Capitalization: $140.99 million

P/E Ratio: 20.26
Dividend Yield: N/A
Price Target: $0.85

MariMed MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 107.3% Upside
$0.85 Price Target
Short Interest: Healthy
0.01% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
MariMed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $0.85, MariMed has a forecasted upside of 107.3% from its current price of $0.41.
Amount of Analyst Coverage
MariMed has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.01% of the outstanding shares of MariMed have been sold short.
Short Interest Ratio / Days to Cover
MariMed has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in MariMed has recently increased by 13.75%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
MariMed does not currently pay a dividend.
Dividend Growth
MariMed does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MRMD.

0.6

News and Social Media Coverage

Search Interest
1 people have searched for MRMD on MarketBeat in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MariMed insiders have not sold or bought any company stock.
Percentage Held by Insiders
23.34% of the stock of MariMed is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 0.27% of the stock of MariMed is held by institutions.

1.3

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of MariMed is 20.51, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.58.
Price to Earnings Ratio vs. Sector
The P/E ratio of MariMed is 20.51, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 91.05.
Price to Book Value per Share Ratio
MariMed has a P/B Ratio of 2.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About MariMed (OTCMKTS:MRMD) Stock

MariMed, Inc. engages in direct owning of cannabis licenses and management of seed-to-sale operations. It focuses on the development, operation, management, and optimization of facilities for the cultivation, production, and dispensing of medicinal and recreational cannabis and cannabis-infused products. The company was founded by Robert N. Fireman and Jon Levine on January 25, 2011 and is headquartered in Norwood, MA.

Receive MRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MariMed and its competitors with MarketBeat's FREE daily newsletter.

MRMD Stock News Headlines

May 22, 2023 | fool.com

MariMed (OTC: MRMD)

May 10, 2023 | finanznachrichten.de

MariMed Inc.: MariMed Reports First Quarter 2023 Earnings

May 31, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

May 10, 2023 | msn.com

MariMed Reports Earnings: Q1 Revenue Falls 4% Sequentially, CEO Pleased With 'Solid Quarter'

May 8, 2023 | finance.yahoo.com

MariMed Reports First Quarter 2023 Earnings

April 29, 2023 | americanbankingnews.com

Contrasting MariMed (OTCMKTS:MRMD) and Mannatech (NASDAQ:MTEX)

April 27, 2023 | americanbankingnews.com

MariMed (OTCMKTS:MRMD) & Jushi (OTCMKTS:JUSHF) Head to Head Survey

April 25, 2023 | finance.yahoo.com

MariMed Announces Opening of Panacea Wellness Dispensary in Beverly, Massachusetts

May 31, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

April 19, 2023 | americanbankingnews.com

MariMed Inc. (OTCMKTS:MRMD) Short Interest Update

April 17, 2023 | finance.yahoo.com

MariMed Expands Board With the Addition of Kathleen Tucker

April 11, 2023 | finance.yahoo.com

MariMed Announces First Quarter 2023 Earnings Date

April 4, 2023 | finance.yahoo.com

MariMed Receives Approval to Once Again Produce and Sell High-Dosage Edibles in Maryland

April 3, 2023 | finance.yahoo.com

MariMed to Participate in Upcoming Investor Conferences

April 2, 2023 | americanbankingnews.com

MariMed (OTCMKTS:MRMD) and Tauriga Sciences (OTCMKTS:TAUG) Head to Head Comparison

March 25, 2023 | benzinga.com

MariMed Stock (OTC:MRMD), Dividends

March 6, 2023 | finance.yahoo.com

MariMed Inc. (PNK:MRMD) Q4 2022 Earnings Call Transcript

March 5, 2023 | finanznachrichten.de

MariMed Inc.: MariMed Reports Fourth Quarter and Full Year 2022 Financial Results

March 5, 2023 | msn.com

Latest Executive Changes In Marijuana Industry, New Appointments & More

March 1, 2023 | finance.yahoo.com

MariMed Reports Fourth Quarter and Full Year 2022 Financial Results

March 1, 2023 | finance.yahoo.com

MariMed Board of Directors Appoints Edward Gildea as Chairman and Jon Levine as Chief Executive Officer

February 21, 2023 | finance.yahoo.com

MariMed To Expand Footprint in Massachusetts With Dispensary Acquisition in Quincy

February 1, 2023 | finance.yahoo.com

MariMed Announces Fourth Quarter 2022 Earnings Date

January 24, 2023 | finance.yahoo.com

MariMed Closes $35 Million Credit Facility to Accelerate its Strategic Growth Plans

January 17, 2023 | finance.yahoo.com

MariMed Strengthens Sales, Marketing, and R&D Teams With Senior Executive Hires

December 30, 2022 | insidermonkey.com

MariMed Inc. (OTC:MRMD) Q3 2022 Earnings Call Transcript

December 21, 2022 | finance.yahoo.com

MariMed Adds Candy Cane Flavored Vape Pen To Its InHouse Brand Line-up for the Holiday Season

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MariMed and its competitors with MarketBeat's FREE daily newsletter.

MRMD Company Calendar

Last Earnings: 11/15/2021
Today: 5/31/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Medicinals & botanicals
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:MRMD
CUSIP: N/A
CIK: 1522767
Web: marimedadvisors.com
Phone: (617) 795-5140
Fax: N/A
Employees: 260
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $0.85
High Stock Price Forecast: $0.85
Low Stock Price Forecast: $0.85
Forecasted Upside/Downside: +107.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.02
Trailing P/E Ratio: 20.51
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $13.47 million
Net Margins: 6.30%
Pretax Margin: 9.80%
Return on Equity: 17.80%
Return on Assets: 6.40%

Debt

Debt-to-Equity Ratio: 0.73
Current Ratio: 2.42
Quick Ratio: 1.50

Sales & Book Value

Annual Sales: $134.01 million
Price / Sales: 1.07
Cash Flow: $0.06 per share
Price / Cash Flow: 6.81
Book Value: $0.19 per share
Price / Book: 2.16

Miscellaneous

Outstanding Shares: 348,130,000
Free Float: 266,874,000
Market Cap: $142.73 million
Optionable: Not Optionable
Beta: 3.02

Key Executives

Jon R. Levine
President, CEO, Secretary, Treasurer & Director

Timothy Shaw
Chief Operating Officer

Susan M. Villare
Chief Financial Officer

Jay O’Malley
Vice President-Marketing & Research & Development

Ryan Crandall
Chief Revenue Officer

Key Competitors

View All Competitors

MRMD Stock - Frequently Asked Questions

Should I buy or sell MariMed stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MariMed in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MRMD shares.
View MRMD analyst ratings or view top-rated stocks.
What is MariMed's stock price forecast for 2023?: 1 brokerages have issued 1-year price targets for MariMed's shares. Their MRMD share price forecasts range from $0.85 to $0.85. On average, they anticipate the company's stock price to reach $0.85 in the next twelve months. This suggests a possible upside of 107.3% from the stock's current price.
View analysts price targets for MRMD or view top-rated stocks among Wall Street analysts.
How have MRMD shares performed in 2023?: MariMed's stock was trading at $0.3562 on January 1st, 2023. Since then, MRMD shares have increased by 15.1% and is now trading at $0.41.
View the best growth stocks for 2023 here.
Are investors shorting MariMed?: MariMed saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 16,000 shares, an increase of 100.0% from the April 15th total of 8,000 shares. Based on an average daily volume of 512,100 shares, the days-to-cover ratio is presently 0.0 days.
View MariMed's Short Interest.
How were MariMed's earnings last quarter?: MariMed Inc. (OTCMKTS:MRMD) announced its quarterly earnings results on Monday, November, 15th. The company reported $0.01 earnings per share (EPS) for the quarter. The company had revenue of $33.21 million for the quarter. MariMed had a trailing twelve-month return on equity of 17.80% and a net margin of 6.30%.
What guidance has MariMed issued on next quarter's earnings?: MariMed updated its FY 2023 earnings guidance on Monday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $150.00M-, compared to the consensus revenue estimate of $149.65 million.

What other stocks do shareholders of MariMed own?: Based on aggregate information from My MarketBeat watchlists, some companies that other MariMed investors own include KushCo (KSHB), Organigram (OGI), Auxly Cannabis Group (CBWTF), CNBX Pharmaceuticals (CNBX), Supreme Cannabis (SPRWF), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), GB Sciences (GBLX), Medical Marijuana (MJNA) and Smart Cannabis (SCNA).
What is MariMed's stock symbol?: MariMed trades on the OTCMKTS under the ticker symbol "MRMD."
How do I buy shares of MariMed?: Shares of MRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is MariMed's stock price today?: One share of MRMD stock can currently be purchased for approximately $0.41.
How much money does MariMed make?: MariMed (OTCMKTS:MRMD) has a market capitalization of $142.73 million and generates $134.01 million in revenue each year. The company earns $13.47 million in net income (profit) each year or $0.02 on an earnings per share basis.
How many employees does MariMed have?: The company employs 260 workers across the globe.
How can I contact MariMed?: MariMed's mailing address is 11 ROYAL ROAD, BROOKLINE MA, 02445. The official website for the company is marimedadvisors.com. The company can be reached via phone at (617) 795-5140 or via email at ir@mattio.com.

This page (OTCMKTS:MRMD) was last updated on 5/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial